Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo.
about
Glutathione S-transferase omega in the lung and sputum supernatants of COPD patientsReciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosisGlutathione redox control of asthma: from molecular mechanisms to therapeutic opportunitiesTransforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer ProgressionThioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signalingActivation of the glutaredoxin-1 gene by nuclear factor κB enhances signalingOxidative stress and glutathione in TGF-beta-mediated fibrogenesisRedox control of asthma: molecular mechanisms and therapeutic opportunities.Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of I{kappa}B kinases in mice: impact on histone acetylation.Redox processes inform multivariate transdifferentiation trajectories associated with TGFβ-induced epithelial-mesenchymal transitionModulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary diseaseCigarette smoke targets glutaredoxin 1, increasing s-glutathionylation and epithelial cell death.Modulation of glutaredoxin-1 expression in a mouse model of allergic airway diseaseStrategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease.Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases.Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis.Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosisRole of N-acetylcysteine in the management of COPDAirway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives.Regulation by reversible S-glutathionylation: molecular targets implicated in inflammatory diseases.In situ analysis of protein S-glutathionylation in lung tissue using glutaredoxin-1-catalyzed cysteine derivatization.Molecular mechanisms and clinical implications of reversible protein S-glutathionylation.Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum of asthmatics.Glutaredoxin-1 attenuates S-glutathionylation of the death receptor fas and decreases resolution of Pseudomonas aeruginosa pneumonia.Regulation of apoptosis through cysteine oxidation: implications for fibrotic lung disease.New insights into the role of oxidative stress in scleroderma fibrosis.The glutathione system: a new drug target in neuroimmune disorders.Glutaredoxin regulates autocrine and paracrine proinflammatory responses in retinal glial (muller) cells.Dietary Flaxseed Oil Protects against Bleomycin-Induced Pulmonary Fibrosis in RatsRedox-Inactive Peptide Disrupting Trx1-Ask1 Interaction for Selective Activation of Stress Signaling.
P2860
Q21284410-AEBFE821-EBA4-486C-93D4-E4C7A2CDA653Q26779846-0897630B-9639-4C51-A73D-DE4E4E7665B1Q27694579-6DADA972-6769-4401-9772-44EF75F17130Q28083526-5728A99A-E1A8-4B72-9311-25681CA388EEQ28389739-57518692-2892-48FF-AF23-F1D2A9D5CF26Q28392256-16403E50-B24E-4A43-8E95-DC58FB6DE106Q28393454-3C284B54-7558-4FC6-B750-582BF6488C30Q33668491-3D5D6C85-4E6B-4F5C-9C66-ED0BAC3C4A0BQ34085544-6A80E887-6D60-42E5-973E-E232094B07ADQ34623170-AD37FF07-9487-4FAA-A8EB-6DB9AE017B21Q35125384-5E6DEB9C-AFFF-4299-9A47-5B93A90EF27AQ35684883-3FED214F-77A7-487C-B375-6EBD4A54A635Q35855278-343D27B3-10BE-48B4-8139-305DBAC63F17Q36036223-173041FB-8EE8-4C1E-9D3B-8472039F965BQ36128020-C014B38D-2AB8-4DF6-9845-154D5154C9F6Q36215313-65F25823-95F1-433C-B680-2102FB9430C4Q36893845-1ECB83BE-4F25-49DF-BB76-02CF37FFE7D8Q36940906-777A6D94-3EA7-4C05-966D-3BEF200B36D0Q37017349-18F86DB1-26E5-43A9-A24E-B25DB420EB31Q37115894-73D8EA91-047D-4D9D-99A3-2790466B6F15Q37165144-F44E65CC-F2F8-4924-8C71-8C55C199E905Q37257106-D7A07F93-C4F2-4D78-94DB-BD60D0BAA778Q37262124-71100DDF-9B1B-44EC-ADAF-483FE1A425B2Q37373767-DDC4F925-BBEC-4078-81D2-76880242FD2EQ37688517-0D236E2F-B46A-4EDA-BA41-EA2ACC6E3FA8Q37780586-2F0E78AD-236C-488D-9758-FFB6FBB1338EQ38026841-DEFE0923-9B33-47C7-B871-F014369E5BA6Q38206126-2EBFA61C-29F8-4DD6-BF76-0C73A4FA1E87Q39906365-A4D239C9-11EF-44AB-A8F5-07F652CAAB03Q42285076-1F205A73-A72F-441D-8756-63E01B243B33Q47271512-8F443F0B-56F7-4641-B008-7D8ACD4B7866
P2860
Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@ast
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@en
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@nl
type
label
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@ast
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@en
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@nl
prefLabel
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@ast
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@en
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@nl
P2093
P1433
P1476
Expression of glutaredoxin is ...... stitial lung diseases in vivo.
@en
P2093
Arne Holmgren
Marjaana Säily
Mirva Peltoniemi
Paavo Pääkkö
Raija Sormunen
Riitta Kaarteenaho-Wiik
Vuokko L Kinnula
P304
P356
10.1016/J.HUMPATH.2004.04.009
P407
P50
P577
2004-08-01T00:00:00Z